First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors

被引：2

作者：

Angevin, E. ^{[1
]}

Kelly, K. ^{[2
]}

Heist, R. ^{[3
]}

Morgensztern, D. ^{[4
]}

Weekes, C. ^{[5
]}

Bauer, T. M. ^{[6
]}

Ramanathan, R. K. ^{[7
]}

Nemunaitis, J. ^{[8
]}

Fan, X. ^{[9
]}

Olyaie, O. ^{[9
]}

Parikh, A. ^{[9
]}

Reilly, E. ^{[10
]}

Afar, D. ^{[9
]}

Naumovski, L. ^{[9
]}

Strickler, J. ^{[11
]}

机构：

[1] Gustave Roussy, Early Drug Dev Dept, Villejuif, France

[2] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA 95817 USA

[3] Massachusetts Gen Hosp, Children Canc Ctr, Boston, MA 02114 USA

[4] Washington Univ, Sch Med, Oncol, St Louis, MO USA

[5] Univ Colorado, Dept Med, Ctr Canc, Anschutz Canc Pavil, Aurora, CO USA

[6] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[7] Mayo Clin, Ctr Canc, Hematol Oncol, Phoenix, AZ USA

[8] Mary Crowley Canc Res Ctr, Oncol, Dallas, TX USA

[9] AbbVie, Biotherapeut, Redwood City, CA USA

[10] AbbVie Inc, Oncol, N Chicago, IL USA

[11] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

来源：

关键词：

D O I：

10.1093/annonc/mdw368.14

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

371P

引用

页数：1